Sensus Healthcare, INC

Sensus Healthcare has entered into a new $15 million revolving credit facility with City National Bank of Florida to support working capital needs.

Sensus Healthcare, Inc. reported on its Annual Meeting of Stockholders held on May 29, 2026, where directors were elected and executive compensation was approved.

Sensus Healthcare announced its fourth quarter and full-year 2025 financial results, reporting significant losses but expressing optimism for 2026 profitability driven by new dedicated CPT codes for SRT.

Sensus Healthcare, Inc. announced the appointment of Carr, Riggs & Ingram, LLC as its new independent registered public accounting firm, replacing Berkowitz Pollack Brant Advisors + CPAs, LLP.

Sensus Healthcare, Inc. announced the appointment of Larry Biscotti, President of Imaging for U.S. and Canada at GE HealthCare, to its Board of Directors, effective immediately.

Sensus Healthcare, Inc. announced the appointment of Eric Sachetta as a Class II director, filling a vacancy and joining the Audit Committee.

Sensus Healthcare reports a significant revenue decrease in Q1 2026 due to fewer unit sales and a shift towards service-based revenue models, impacting gross margins.

Sensus Healthcare reported a significant net loss in Q3 2025, driven by a 22% revenue decrease and substantial increases in operating expenses, despite an improved cash position.

Sensus Healthcare, Inc. reported a significant net loss and revenue decline for the second quarter and first half of 2025, primarily due to lower unit sales to a major customer and increased operating expenses.

Sensus Healthcare's Q1 2025 results reveal a decrease in revenue and a net loss, driven by lower sales and increased operating expenses.

Sensus Healthcare's Q3 2024 results show a significant increase in revenue driven by higher unit sales to a major customer, alongside improvements in gross profit.

Sensus Healthcare's Q2 2024 results show a significant increase in revenue, driven by higher unit sales, but also reveal a material weakness in internal controls.

Sensus Healthcare, Inc. reported a net loss of $7.7 million in 2025, a significant decline from the prior year's profit, driven by reduced sales and increased operating expenses.

Sensus Healthcare achieved significant revenue growth and profitability in 2024, driven by increased unit sales of its SRT-100 product line.

Sensus Healthcare's 2023 annual report reveals a decrease in revenue and a shift to profitability, impacted by inflationary pressures and customer purchase deferrals.

Sensus Healthcare Director Eric Sachetta acquired 1,500 shares of common stock.

Sensus Healthcare director Eric Sachetta amends prior filing to accurately reflect beneficial ownership of 2,093 shares held indirectly through his spouse.

CFO Javier Rampolla filed an amendment to correct an overstatement of 742 shares in his previously reported beneficial ownership.

Magdalena Martinez, Chief Operating Officer of Sensus Healthcare, Inc., filed an amendment to her beneficial ownership statement, correcting previously reported shareholdings.

Sensus Healthcare Director Eric Sachetta purchased 2,000 shares of common stock at an average price of $3.81, increasing his beneficial ownership.

Sensus Healthcare, Inc. granted 40,000 shares of restricted common stock to Michael Sardano, President and General Counsel, under its 2017 Equity Incentive Plan.

Sensus Healthcare, Inc. has issued its definitive proxy statement, announcing the 2026 Annual Meeting of Stockholders scheduled for May 29, 2026, to elect directors and vote on executive compensation.

Sensus Healthcare's proxy statement details proposals for the 2025 annual meeting, including the election of a Class I director, an amendment to the 2017 Incentive Plan, an advisory vote on executive compensation, and ratification of the independent accounting firm.

Sensus Healthcare's proxy statement outlines proposals for the upcoming annual meeting, including director elections, officer liability limitations, executive compensation, and auditor ratification.

Joseph C. Sardano has filed an amended Schedule 13G, revealing a 7.1% beneficial ownership stake in Sensus Healthcare, Inc., comprising 1,175,293 shares of common stock.

Edwin L. Solot, Jr. has filed an amended Schedule 13G, reporting a 7.6% passive beneficial ownership stake in Sensus Healthcare, Inc. as of December 31, 2024.